Acycloguanosine (ACG) was able to prevent the fatal outcome of herpes simplex virus-induced skin infections of the lumbosacral or orofacila area in hairless mice. Topical ACG treatment was more effective than systemic treatment in preventing the evolution of skin lesions. Acute ganglionic infections in the trigeminal ganglia were prevented by ACG, and latent ganglionic infections did not become established when the ACG treatment was initiated 3 h after infection. Serum antibody titers were, on the average, eight times higher in mice which developed latent ganglionic infections after ACG treatment than in mice without evidence of herpes simplex virus latency in ganglia. Reinoculation of ACG-treated mice at a site different from that of the primary inoculation did not lead to the establishment of a second latent infection with the homologous virus type when a latent infection was already present. In mice without evidence of latent infection after the primary inoculation, a latent infection at the site of reinoculation became established in 25% of the animals. (8) have shown that ACG, on a molar basis, is about 10 times more potent than 5-iodo-2'-deoxyuridine, 160 times more active than adenine arabinoside (Ara-A), and about 600 times more active than phosphonoacetic acid (PAA). ACG was tested for activity in mice infected intracerebrally with HSV: given by the oral route or subcutaneously in a dose of 100 mg/kg of body weight twice daily for 5 days, the compound increased the survival time of infected mice (8). ACG ointments were also evaluated in experimental herpetic keratitis in rabbits and in HSV-induced lesions in guinea pigs. In both models, the substance conferred good protection against the infections (2, 8) . No quantitative data regarding the skin infections were given in the above-mentioned experiments.
Acycloguanosine (ACG) was able to prevent the fatal outcome of herpes simplex virus-induced skin infections of the lumbosacral or orofacila area in hairless mice. Topical ACG treatment was more effective than systemic treatment in preventing the evolution of skin lesions. Acute ganglionic infections in the trigeminal ganglia were prevented by ACG, and latent ganglionic infections did not become established when the ACG treatment was initiated 3 h after infection. Serum antibody titers were, on the average, eight times higher in mice which developed latent ganglionic infections after ACG treatment than in mice without evidence of herpes simplex virus latency in ganglia. Reinoculation of ACG-treated mice at a site different from that of the primary inoculation did not lead to the establishment of a second latent infection with the homologous virus type when a latent infection was already present. In mice without evidence of latent infection after the primary inoculation, a latent infection at the site of reinoculation became established in 25% of the animals.
It has been recently shown by Elion et al. (1) that a guanine derivative with an acyclic side chain, 9-(2-hydroxyethyoxymethyl) -guanine (acycloguanosine [ACG] ), is a potent in vitro inhibitor of herpes simplex virus type 1 (HSV-1). In HSV-infected cells ACG is converted to its triphosphate, which acts as a selective inhibitor of HSV deoxyribonucleic acid nucleotidyltransferase. ACG serves as a substrate for HSVspecific thymidine kinase; cellular thymidine kinase which occurs naturally in uninfected cells does not effectively utilize ACG as a substrate. Subsequent studies (8) have shown that ACG, on a molar basis, is about 10 times more potent than 5-iodo-2'-deoxyuridine, 160 times more active than adenine arabinoside (Ara-A), and about 600 times more active than phosphonoacetic acid (PAA). ACG was tested for activity in mice infected intracerebrally with HSV: given by the oral route or subcutaneously in a dose of 100 mg/kg of body weight twice daily for 5 days, the compound increased the survival time of infected mice (8) . ACG ointments were also evaluated in experimental herpetic keratitis in rabbits and in HSV-induced lesions in guinea pigs. In both models, the substance conferred good protection against the infections (2, 8) . No quantitative data regarding the skin infections were given in the above-mentioned experiments. In the present study we have evaluated the efficacy of ACG in HSV-induced skin infections in hairless mice. The evaluation was based upon the effect on skin lesions, the mean survival time, and the mortality rate. The pathogenesis of the HSV-induced skin infection during the treatment and the specific antibody response were likewise investigated. As we have pointed out in a previous study (3) , evaluation of the effectiveness of any chemotherapeutic agent active against HSV infection should include the determination of its ability to prevent the establishment of latent infections in the sensory ganglia after the primary infection. It was shown that PAA affords good protection against the establishment oflatent infections in sensory ganglia (5, 6, 12) , whereas Ara-A and Ara-A-monophosphate are much less effective (3, 6 
MATERLALS AND METHODS
Virus. The S strain of HSV-1, used throughout this experiment, and the Gordon strain of HSV-2 have been described previously (4, 5 (3, 5) , whereas the frequency of latent infections in the trigeminal ganglia of orofacially inoculated mice approaches 100% (4, 6) . Therefore, the effect of antiviral treatments on the mortality rate and severity of skin lesions was estimated from lumbosacrally inoculated mice, and the frequency of latent infections after treatment of the primary infection was estimated from mice inoculated in the orofacial area.
Procedures for cocultivation of mouse ganglia, serum HSV-specific antibody titration, and monitoring the establishment of acute and chronic virus infections in the ganglia have been described in previous publications (3, 5, 6 In mice inoculated in the lumbosacral area the 5% gel and ointment almost completely prevented the development of skin lesions when the treatment was initiated 3 h after virus inoculation. Only mild lesions, which healed rapidly, were observed when mice were treated with the 1% gel or ointment (Fig.1) . The 5% gel applied 24 and 48 h after virus inoculation curtailed the development of skin lesions, and the lesions already present healed rapidly (Fig. 2) . Similar results were observed when topical treatment with the 5% ointment was initiated 24 h after virus inoculation. All mice treated with the 1% or 5% ACG gel and ointment according to various schedules survived. The observed mortality rate in parallel placebo-treated mice was 100% (Table 2) .
Latent infections in the spinal ganglia were not detected in mice treated 3 h after infection with either the 1% or the 5% ointment. When Table 4 .
We have noted that the virus reactivation time, i.e., the time elapsed from the initiation of ganglion cultures until the appearance of the virus-induced cytopathic effect, was 10 days for ganglia from the two ACG-treated mice, whereas it required only 5 days for the ganglia of the four placebo-treated mice. This was not an isolated observation, since the virus reactivation time from latently infected ganglia of ACG-treated mice was consistently longer than the virus reactivation time from ganglia of placebo-treated mice. In ganglia of placebo-treated mice the mean virus reactivation time was 4 days (range, 3 to 5 days), whereas in ACG-treated mice this interval increased to almost 8 days (range, 4 to 10 days) ( Table 5) .
Resistance to reinfection of ACG-treated mice. Groups of mice inoculated in the lumbosacral area with HSV-1 and treated with ACG were reinoculated 3 to 4 weeks later in the orofacial region with HSV-1 or HSV-2 (Table 6) . No lesions were observed after reinoculation in mice treated systemically, but 8 out of the 19 mice treated topically developed small lesions. In 7 out of the 34 reinoculated mice a latent infection became established in the trigeminal ganglia ( Table 6 ). The 5% ACG gel-treated mice with latent infections in the trigeminal ganglia were among those which developed lesions after reinoculation. Six latent infections in the trigeminal ganglia became established in mice without evidence of latent infections in the spinal ganglia. Only 1 mouse was found to have latent HSV infections in the spinal ganglia (established after the primary infection in the lumbosacral area) and in the trigeminal ganglia (established after reinoculation in the orofacial region). Neutralization with HSV type-specific rabbit antisera showed that the virus reactivated from the spinal ganglia was HSV-1, whereas the virus isolated from the trigeminal ganglia was HSV-2.
DISCUSSION
Our results indicate that HSV-induced skin infections in hairless mice can be successfully treated topically with ACG gels and ointments. Similar results have been presented by Schaeffer et al. (8) in skin infections of guinea pigs. When a 1% ACG ointment was applied twice daily for 3 days on the percutaneously infected guinea pigs, the treated sites healed in about 3 days, whereas on the untreated sites the lesions were still in progress (8) . However, HSV infections in guinea pigs are mild, and central nervous system involvement with a fatal outcome is a rare event (10). E. R. Kern, J. T. Richards, J. C. Overall, Jr., and L. A. Glasgow (Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother., 18th, Atlanta, Ga., Abstr. no. 264, 1978) have shown that mice inoculated intravaginally with HSV-2 and treated with ACG showed a statistically significant reduction in the intensity of vaginal lesions, a decrease of the mortality rate, and a reduction of virus shedding from the vaginal lesions. No data were provided regarding the ability of the ACG to prevent the establishment oflatent HSV infections in the sensory ganglia of the guinea pigs or mice. HSV from the spinal ganglia was of type 1, and that from the trigeminal ganglia was of type 2, as determined by neutralization with type-specific rabbit sera.
Our results show that topically applied ACG preparations given as late as 48 h after virus inoculation in the lumbosacral or orofacial area, when lesions are already present, can prevent their further evolution. Although the mortality rate among placebo-treated mice was 100%, none of the ACG-treated mice died, even when the treatment was delayed for 48 h after virus inoculation in the lumbosacral area. It appears also that when ACG treatment is applied 3 h after infection, no latent HSV infections are established in the sensory ganglia. However, when the treatment was delayed or when the concentration of the drug in the ointments was decreased, an increase in the frequency of latent ganglionic infections was observed. This shows that ACG has little effect on the virus which has already invaded the ganglion.
Compared to other antiviral agents, ACG seems to be the most effective and least toxic compound in the treatment of HSV skin infections in mice which we have evaluated to date. We have shown that Ara-A and Ara-A-monophosphate, applied topically, can reduce the intensity of skin lesions and reduce significantly the mortality rate, but cannot prevent the establishment of latent HSV infections in the spinal or trigeminal ganglia (3, 6) . Among the tested antiviral agents, only PAA had the ability to prevent both skin lesions and the eventual development of latent infections in sensory ganglia (5, 6, 12) . However, the effectiveness of PAA decreased sharply when the treatment was delayed, and the compound also had an irritating effect on the skin. No such irritations were observed in ACG-treated mice.
The results obtained with ACG treatment substantiated our observations made with Ara-A, Ara-A-monophosphate, and PAA that the orofacial route of inoculation provides a reliable estimate of the ability of an antiviral compound to prevent the establishment of latent HSV infections in the trigeminal ganglia (6) . As opposed to the orofacial route of inoculation, the lumbosacral route yields somewhat irregular responses due to the fact that latent infections can be detected only in 60 to 70% of the untreated mice surviving the viral infection. However, the latter route of inoculation is a critical test in estimating the ability of an antiviral agent active against HSV to prevent the fatal outcome of the skin infection.
The experiments described showed that topical treatment with ACG prevented virus penetration of cutaneous nerve endings, since no free virus was generally detected in trigeminal ganglion homogenates. We have observed a relationship between the amount of free virus in the ANTIMICROB. AGENTS CHEMOTHER.
on June 25, 2017 by guest http://aac.asm.org/ Downloaded from ganglia during the acute phase of the infection and the virus reactivation time in cocultivated latently infected ganglia (6) . When ACG-treated mice develop latent ganglionic infection, the virus reactivation time is about twice as long as that found in the ganglia of placebo-treated mice. Our data do not provide information as to the actual number of latently infected cells in the ganglia, but Walz et al. (11) have shown that about 0.1% of the ganglionic cells are infected and that if the immune response of the mouse inhibits viral replication in the skin, the number of cells becoming infected would be reduced correspondingly. This conclusion may be extended to include drug treatments which inhibit virus replication in the skin, thus reducing the number of ganglionic cells which become latently infected. Since ganglia from treated mice are cocultivated in fragments, it is easily conceivable that virus reactivated in a few cells, some of them located deep inside the fragment, may require a longer time to be released and reach the indicator cells where the cytopathic effect is observed than would virus reactivated from ganglia of untreated mice, containing 10 to 100 times more latently infected cells.
Mice in which treatment with ACG was initiated 3 h after infection had low or undetectable levels of serum antibodies. It appears from our results that some of these mice can be reinfected with subsequent establishment of a latent ganglionic infection if the reinoculation is performed at a site distant from that of the primary infection. Similar results were obtained previously in mice reinoculated at a different site after PAA treatment of the primary infection (4) . In mice with latent infections in the ganglia innervating the site of primary infection, the establishment of latent infections in the ganglia innervating the area of reinoculation was prevented. In the present experiments, only 1 out of the 10 mice with latent infections in the spinal ganglia developed a latent infection in the trigeminal ganglia after reinoculation with the heterologous virus type.
Although McKendall (7) has shown that immunity to HSV-1 in mice protects against acute and latent infections with HSV-2, it appears that protection is not absolute. Recently, it was shown (9) that in mice immunized with HSV-1, 40% of the mice surviving the vaginal challenge with HSV-2 developed latent ganglionic infections. This relatively low protection rate can be accounted for by the immunization procedure, which avoided the establishment of latent infections by intraperitoneal administration of the virus. In our present and previous experiments (4) a total of 65 mice surviving the primary infection in the lumbosacral region were reinoculated in the orofacial area. In 46 mice without latent infections in the spinal ganglia, 12 displayed latent infections in trigeminal ganglia (26%), whereas in 19 mice with latent HSV in the spinal ganglia, only 1 was detected with a latent infection in the trigeminal ganglion (5%). The difference is statistically significant (P < 0.05) and indicates that double latent ganglionic HSV infections in mice are a rare event.
